Lexicon Pharmaceuticals | LXRX - Sales Revenues

Stock Price
1.31
Daily Change
0 0%
Monthly
5.65%
Yearly
66.90%
Q1 Forecast
2.01

Lexicon Pharmaceuticals reported $1.65M in Sales Revenues for its fiscal quarter ending in June of 2024.





Sales Change Date
Abbott USD 11.46B 90M Dec/2025
Acadia Pharmaceuticals USD 278.6M 14M Sep/2025
Agios Pharmaceuticals USD 19.97M 7.07M Dec/2025
Akebia Therapeutics USD 57.34M 10.84M Mar/2025
Alnylam Pharmaceuticals USD 1.1B 150M Dec/2025
AstraZeneca USD 15.5B 313M Dec/2025
BioMarin Pharmaceutical USD 776M 49M Sep/2025
Coherus Biosciences USD 7.6M 46.54M Mar/2025
Eli Lilly USD 19.3B 1.7B Dec/2025
Esperion Therapeutics USD 51.63M 22.2M Sep/2024
Halozyme Therapeutics USD 354M 148M Sep/2025
Illumina USD 1.16B 80M Dec/2025
Insmed USD 142M 34.6M Sep/2025
Ironwood Pharmaceuticals USD 122.06M 36.82M Sep/2025
J&J USD 24.6B 610M Dec/2025
Lexicon Pharmaceuticals USD 1.65M 520K Jun/2024
MacroGenics USD 72.84M 50.6M Sep/2025
MannKind USD 82.13M 5.6M Sep/2025
Merck USD 16.4B 880M Dec/2025
Moderna USD 678M 342M Dec/2025
Novartis USD 13.91B 144M Sep/2025
PTC Therapeutics USD 211M 32.1M Sep/2025
Puma Biotechnology USD 80.54M 33.46M Sep/2024
Sarepta Therapeutics USD 399.4M 211.69M Sep/2025
Thermo Fisher Scientific USD 12.21B 1.09B Dec/2025
Ultragenyx Pharmaceutical USD 207M 47M Dec/2025
United Therapeutics USD 799.5M 900K Sep/2025
Vanda Pharmaceuticals USD 198.77M 151.12M Dec/2024